March 14, 2019

Non Invasive Prenatal Testing Market| Market Trends by Instruments, Consumables, Method, Applicationand End User

The major factors driving the growth of this market include the growing preference for non-invasive techniques over invasive methods, rising focus on reimbursement for NIPT, launch of new and advanced NIPT products, and increasing maternal age (associated with growth in the risk of chromosomal abnormalities in babies). Furthermore, untapped emerging markets are expected to offer potential growth opportunities to players operating in the NIPT market during the forecast period.

The non-invasive prenatal testing (NIPT) market is expected to reach USD 2.88 billion by 2021 from USD 1.35 billion in 2016, at a CAGR of 16.4% from 2016 to 2021.

The instruments segment is divided into ultrasound device, NGS systems, PCR instruments, microarrays, and other instruments. In 2016, the consumables segment accounted for the largest share of the market. The high growth in this segment is attributed to the repeated requirements of consumables as compared to instruments in NIPT.

Based on application, the market is divided into Trisomy, microdeletion syndrome, and other applications. Trisomy forms the largest and fastest-growing application segment of the global market. This is mainly attributed to the rising incidence of chromosomal abnormalities with increasing maternal age.

The global market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). The market in Asia is expected to grow at the highest CAGR during the forecast period. Factors such as increasing awareness programs, high incidence of genetic disorders, increasing healthcare infrastructure, and rising disposable income are some of the factors contributing to the growth of the market in Asia.

Key Players:

Key market players are GE Healthcare (U.S.), Koninklijke Philips N.V. (Netherlands), Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Pacific Biosciences of California, Inc. (U.S.), PerkinElmer, Inc. (U.S.), QIAGEN N.V. (Germany), Agilent Technologies, Inc. (U.S.), and Beijing Genomics Institute (China).

Get More Details @ https://www.marketsandmarkets.com/Market-Reports/non-invasive-prenatal-testing-market-145607690.html